Publications

Journal Article Ppublish 301 citations
Electronic publication date
April 1, 1991

View on Pubmed.gov 1900527 | View on doi.org 10.1111/j.1471-...

The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons.

Search for publications in this journal J Neurochem - 56(4):1441-4

Abstract

A selective increase in content of iron in the pars compacta of the substantia nigra has been implicated in the biochemical pathology of Parkinson's disease. Iron is thought to induce oxidative stress by liberation of oxygen free radicals from H2O2. Because 6-hydroxydopamine (6-OHDA) is thought to induce nigrostriatal dopaminergic neuronal lesions via metal-catalyzed free radical formation, the effect of the iron chelator desferrioxamine was investigated on 6-OHDA-induced dopaminergic neuron degeneration in the rat. Intracerebroventricular injection of 6-OHDA (250 micrograms) caused a 88, 79, and 70% reduction in striatal tissue content of dopamine (DA), 3,4-dihydroxyphenylacetic acid, and homovanillic acid (HVA), respectively, and a 2.5-fold increase in DA release as indicated by the HVA/DA ratio. Prior injection of desferrioxamine (130 ng i.c.v.) resulted in a significant protection (approximately 60%) against the 6-OHDA-induced reduction in striatal DA content and a normalization of DA release. Dopaminergic-related behavioral responses, such as spontaneous movements in a novel environment and rearing, were significantly impaired in the 6-OHDA-treated group. By contrast, the desferrioxamine-pretreated rats exhibited almost normal behavioral responses. The ability of iron chelators to retard dopaminergic neurodegeneration in the substantia nigra may indicate a new therapeutic strategy in the treatment of Parkinson's disease.

References

No references provided.

Cited by 301 citations (total)

Journal Article Review

A scientific rationale for protective therapy in Parkinson's disease.

Electronic publication date January 1, 1993

Search for publications in this journal J Neural Transm Gen Sect

C W Olanow

The desire to introduce neuroprotective therapy for Parkinson's disease has begun to focus attention on pathogenetic mechanisms responsible for cell...

Journal Article Research Support, Non-U.S. Gov't Review

The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease.

Electronic publication date March 20, 1999

Search for publications in this journal Drugs Aging

K A Jellinger

Although the aetiology of Parkinson's disease (PD) and related neurodegenerative disorders is still unknown, recent evidence from human and experimental...

Conflict of interest statement

No conflict of interest statement provided.

MeSH

Specialties

Substances